Diabetology International最新文献

{"title":"Acetonemic vomiting: a potential complication of treatment with glucagon-like peptide-1 receptor agonists especially in lean type 2 diabetes patients.","authors":"Midori Fujishiro, Maiko Nosoko, Jin Ikeda, Misaki Takeuchi, Takeshi Yamamotoya, Tadateru Takayama, Tatsuhiko Urakami, Katsuhiko Ogawa, Hisamitsu Ishihara","doi":"10.1007/s13340-024-00758-x","DOIUrl":"10.1007/s13340-024-00758-x","url":null,"abstract":"<p><strong>Objectives: </strong>Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are now widely used for treating type 2 diabetes mellitus (T2DM) and obesity. We examined their association with acetonemic vomiting, especially when given to patients with low body weight, in hopes of achieving early recognition of this complication which is potentially life-threatening if not dealt with appropriately.</p><p><strong>Methods: </strong>Cases identified incidentally are described and discussed referring to prior reports.</p><p><strong>Results: </strong>We managed two episodes of acetonemic vomiting, associated with GLP-1 RA use, affecting type 2 diabetes patients with low body weight. The absence of significant abnormalities in regularly tested laboratory data or imaging workup findings in these patients made it difficult to diagnose and recognize the emergent nature of the problem.</p><p><strong>Conclusion: </strong>GLP1-RAs have the potential to induce acetonemic vomiting when prescribed to patients with diabetes, especially those with low body weight. Although it is a potentially life-threatening disorder, acetonemic vomiting is not common in adults, making accurate diagnosis challenging. It is important that clinicians not hesitate to administer a dextrose-containing intravenous bolus, with insulin if necessary, to maintain normal glucose levels and thereby prevent progression to severe outcomes including death.</p>","PeriodicalId":11340,"journal":{"name":"Diabetology International","volume":"16 1","pages":"162-168"},"PeriodicalIF":1.3,"publicationDate":"2024-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11769917/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143058387","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of angiotensin receptor neprilysin inhibitor on serum C-peptide levels in patients with type 2 diabetes.","authors":"Tatsuya Ishibashi, Nobuyuki Nishi, Masanori Kita, Satomi Uenoyama, Tomomi Nakao, Ken Takeshima, Yasushi Furukawa, Shuhei Morita, Hiroto Furuta, Tokio Sanke, Taka-Aki Matsuoka","doi":"10.1007/s13340-024-00761-2","DOIUrl":"10.1007/s13340-024-00761-2","url":null,"abstract":"<p><p>Sacubitril/valsartan, an angiotensin receptor neprilysin inhibitor (ARNI), is becoming more common in the treatment of heart failure and hypertension. Neprilysin is highly expressed in the renal tubules, and reports have shown increases in urinary C-peptide reactivity (CPR) levels after administration of ARNI. However, the effect of ARNI on serum CPR levels, a critical marker of insulin secretion in diabetes, remains underexplored. We evaluated the effect of ARNI on serum CPR levels in patients with type 2 diabetes and its impact on the assessment of endogenous insulin secretion. We retrospectively investigated the medical records of patients with type 2 diabetes at two hospitals, where fasting plasma glucose and serum CPR levels were measured before and after administration of ARNI. All eleven patients (five males, six females) who met the criteria showed an increase in median fasting serum CPR levels following ARNI administration. The levels rose from a median of 1.78 ng/mL (IQR: 1.26-2.02) to 3.19 ng/mL (IQR: 2.71-5.12), accompanied by significant increases in the C-peptide index. Immunoreactive insulin levels barely changed after ARNI administration, but the ratio of immunoreactive insulin to CPR decreased significantly, from 3.3 (IQR: 2.5-3.9) to 1.6 (IQR: 1.3-1.9). The increase in serum CPR levels is attributed to inhibition of CPR degradation rather than an increase in endogenous insulin secretion, as fasting blood glucose levels remained unchanged. These findings suggest the need for caution when using serum CPR levels to evaluate endogenous insulin secretion in patients treated with an ARNI, which are increasingly being prescribed for heart failure and hypertension.</p>","PeriodicalId":11340,"journal":{"name":"Diabetology International","volume":"16 1","pages":"194-198"},"PeriodicalIF":1.3,"publicationDate":"2024-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11769879/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143058454","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cost-effective analysis focused on hypoglycemia of intermittent-scanning continuous glucose monitoring in type 1 diabetes adults: a ISCHIA randomized clinical trial.","authors":"Naoki Sakane, Munehide Matsuhisa, Akio Kuroda, Junnosuke Miura, Yushi Hirota, Ken Kato, Masao Toyoda, Ryuji Kouyama, Kunichi Kouyama, Akira Shimada, Satoshi Kawashima, Yuka Matoba, Shu Meguro, Yoshiki Kusunoki, Kazuyuki Hida, Tsuyoshi Tanaka, Masayuki Domichi, Akiko Suganuma, Shota Suzuki, Atsuhito Tone, Kiminori Hosoda, Takashi Murata","doi":"10.1007/s13340-024-00762-1","DOIUrl":"10.1007/s13340-024-00762-1","url":null,"abstract":"<p><strong>Background: </strong>This study aimed to compare the economic value of intermittent-scanning continuous glucose monitoring (isCGM) with self-monitoring of blood glucose (SMBG) in adults with type 1 diabetes (T1D).</p><p><strong>Methods: </strong>Participants were placed on either an isCGM or SMBG arm for 84 days, in a randomized, crossover setup with a 28-day washout period. Clinically relevant hypoglycemia (<54 mg/dL) and severe hypoglycemia (SH) risks were calculated by analyzing the data from isCGM. The effectiveness variable was quality-adjusted life years (QALYs), and costs included medical costs related to the SMBG device. In addition, we performed a sensitivity analysis using a tornado diagram to confirm the robustness of the results.</p><p><strong>Patients: </strong>A total of 93 Japanese T1D adults (51.4 ± 15.3 years old, male 47.3%, and HbA1c 7.3 ± 0.7%) treated with multiple daily insulin injection (MDI).</p><p><strong>Results: </strong>Compared to the SMBG arm, clinically relevant hypoglycemia and SH risks over daytime (2.7 ± 1.7 vs. 2.4 ± 1.6 times; <i>P</i> = 0.008 and 3.1 ± 3.2 vs. 2.2 ± 2.7; <i>P</i> = 0.001) and night-time periods (2.1 ± 1.6 → 1.7 ± 1.2; <i>P</i> < 0.001 and 5.1 ± 4.0 → 4.2 ± 3.8; <i>P</i> = 0.013) were reduced with isCGM treatment. The isCGM system was associated with an incremental gain in quality-adjusted life expectancy (QALE) of 0.8 QALYs compared with the SMBG arm (74.6 vs. 73.8 QALYs). The resulting incremental cost-effectiveness ratio was JPY 4,398,932 (US$41,212) per QALY gained, which is well below the generally accepted cost-effectiveness threshold. SH during the daytime period was the primary driver of the incremental QALE.</p><p><strong>Conclusion: </strong>The findings suggest that isCGM use for Japanese T1D adults treated with MDI is cost saving relative to SMBG.</p>","PeriodicalId":11340,"journal":{"name":"Diabetology International","volume":"16 1","pages":"78-85"},"PeriodicalIF":1.3,"publicationDate":"2024-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11769919/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143058444","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dapagliflozin treatment decreases visceral and subcutaneous adipose tissue: a systematic review and meta-analysis.","authors":"Carlos U Vargas-Ramírez, Víctor Posadas-Posadas, Renata Ochoa-Précoma, Leonardo M Porchia, Ricardo Pérez-Fuentes, M Elba Gonzalez-Mejia","doi":"10.1007/s13340-024-00765-y","DOIUrl":"10.1007/s13340-024-00765-y","url":null,"abstract":"<p><strong>Aims: </strong>Sodium-glucose co-transporter-2 inhibitors (SGLT2i) have been shown to reduce visceral (VAT) and subcutaneous (SAT) adipose tissue. Although many systematic reviews have examined SGLT2i's effect on VAT and SAT, a focus analysis of dapagliflozin, one of the more commonly prescribe SGLT2i, has yet to been done. This study aims to determine the effect of dapagliflozin on reducing VAT and SAT in patients with chronic disease.</p><p><strong>Methods: </strong>SCOPUS, PubMed, EBSCO, and LILACS databases were searched until December 26, 2023. Heterogeneity was determined using Cochran's <i>Q</i> test and quantified using the inconsistency index. The random-effects model was used to calculate the pooled standardize difference in means (SDM) and 95% confidence intervals (95% CI). Duval and Tweedie trim and fill (DT), Egger's test, and Beggs-Muzamar's test were used to assess publication bias. PROSPERO: CRD42023426208.</p><p><strong>Results: </strong>Twelve reports were included (treated = 299 and controls = 301). Overall, dapagliflozin treatment reduced VAT (SDM = - 0.406, 95% CI: - 0.526 to - 0.286, <i>p</i> < 0.001) and SAT (SDM = - 0.439, 95% CI: - 0.601 to - 0.278, <i>p</i> < 0.001). These results were stable as determined with a sensitivity analysis; however, there was potential publication bias. Two and three imputed studies were determined by the DT method for VAT and SAT, respectively. When stratified by pathology (obesity, T2D, and T2D/NAFLD), dapagliflozin treatment decreased VAT and SAT for all conditions. However, for specifically SAT, only when compared between T2D and T2D/NAFLD, T2D/NAFLD was associated with a twofold decrease (<i>p</i> = 0.003).</p><p><strong>Conclusion: </strong>Treatment with dapagliflozin resulted in a significant reduction in VAT and SAT in patients with obesity, T2D, or T2D/NAFLD.</p><p><strong>Supplementary information: </strong>The online version contains supplementary material available at 10.1007/s13340-024-00765-y.</p>","PeriodicalId":11340,"journal":{"name":"Diabetology International","volume":"16 1","pages":"65-77"},"PeriodicalIF":1.2,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11769893/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143058445","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of laparoscopic sleeve gastrectomy on weight loss and metabolic improvement in subjects aged 65 years or older: a subanalysis of J-SMART study.","authors":"Yasuhiro Watanabe, Takashi Yamaguchi, Akira Sasaki, Takeshi Naitoh, Hisahiro Matsubara, Koutaro Yokote, Shinichi Okazumi, Satoshi Ugi, Hiroshi Yamamoto, Masayuki Ohta, Yasushi Ishigaki, Kazunori Kasama, Yosuke Seki, Motoyoshi Tsujino, Kohji Shirai, Yasuhiro Miyazaki, Takayuki Masaki, Daiji Nagayama, Ichiro Tatsuno, Atsuhito Saiki","doi":"10.1007/s13340-024-00767-w","DOIUrl":"10.1007/s13340-024-00767-w","url":null,"abstract":"<p><strong>Aim: </strong>To investigate the effect of weight loss and metabolic improvement after laparoscopic sleeve gastrectomy (LSG) in older adults aged 65 years or over compared with younger adults in a retrospective analysis.</p><p><strong>Methods: </strong>The J-SMART study database of 322 Japanese individuals with body mass index (BMI) ≥32 kg/m² who underwent LSG between 2011 and 2014 at 10 centers accredited by the Japanese Society for Treatment of Obesity were analyzed. The subjects were classified into two groups: ≥65 age group (range, 65-76 years; n = 25) and <65 age group (range, 22-64 years; n = 297). Clinical parameters were compared between the groups.</p><p><strong>Results: </strong>Baseline data for the ≥65 vs. <65 age groups were: median age 67 years vs. 45 years; weight 92.7 kg vs. 114.4 kg; BMI 40.0 kg/m² vs. 41.9 kg/m²; and HbA1c 6.8% vs. 6.5%. The ≥65 age group had significantly lower preoperative weight, BMI, estimated glomerular filtration rate, and ABCD score, but higher visceral fat area and prevalence of diabetes, hypertension, and obstructive sleep apnea (OSAS). Weight was significantly reduced in both groups throughout 5 years post-LSG, though total weight loss at 2 years was lower in the ≥65 age group (28.0%) than in the <65 group (30.0%). Remission rates of diabetes, hypertension, OSAS, and joint disorders 2 years after LSG showed no significant differences, except for dyslipidemia.</p><p><strong>Conclusion: </strong>LSG may be an efficacious option for improving obesity-related health problems in older adults. However, postoperative safety and complications were not evaluated in this study and further research is needed.</p><p><strong>Supplementary information: </strong>The online version contains supplementary material available at 10.1007/s13340-024-00767-w.</p>","PeriodicalId":11340,"journal":{"name":"Diabetology International","volume":"16 1","pages":"56-64"},"PeriodicalIF":1.2,"publicationDate":"2024-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11769886/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143058449","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term effect of short-term exercise instructions in Japanese patients with type 2 diabetes: observation study after randomized controlled study.","authors":"Hideto Iida, Takashi Sekiyama, Yoshitaka Hashimoto, Jin Matsushita, Atsushi Shindo, Hiroshi Okada, Hiroaki Murata, Michiaki Fukui","doi":"10.1007/s13340-024-00766-x","DOIUrl":"10.1007/s13340-024-00766-x","url":null,"abstract":"<p><strong>Aims: </strong>To clarify the long-term effects of short-term exercise instructions by physical therapists in Japanese people with type 2 diabetes (T2D).</p><p><strong>Methods: </strong>This was a follow-up study of 2 years after randomized controlled study of short-term exercise instructions included 18 patients (5 in the non-intervention and 13 in the intervention groups). Motor skills, including 6 min walk test scores, and transtheoretical model was evaluated at baseline (week 0)<i>,</i> the end of the study of the previous study (week 8), and 2 years after (2 years).</p><p><strong>Results: </strong>In the intervention group, changes in 6 min walk distance, which was significant at 8 weeks (from 445 (420-480) m to 490 (450-520) m, <i>p</i> = 0.01)), were maintained at 2 years (496 (420-540) m, <i>p</i> = 0.05), whereas in the non-intervention group, there were no changes in 6 min walk distance at 8 weeks (from 460 (458-493) m to 464 (460-485) m, <i>p</i> = 0.86) and 2 years (490 (480-506) m, <i>p</i> = 0.63). Furthermore, the changes in transtheoretical model, which was significant at 8 weeks (<i>p</i> = 0.008), were maintained at 2 years (<i>p</i> = 0.02), whereas in the non-intervention group, there were no changes in 6 min walk distance at 8 weeks and 2 years. On the other hand, the other markers were not significantly different between week 8 and 2 years compared to baseline in both groups.</p><p><strong>Conclusions: </strong>Short-term outpatient exercise instruction by physical therapists may lead to long-term improvement effect on walking ability in people with T2D.</p>","PeriodicalId":11340,"journal":{"name":"Diabetology International","volume":"16 1","pages":"50-55"},"PeriodicalIF":1.2,"publicationDate":"2024-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11769889/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143058456","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analysis of thyroid autoantibodies and the risk of insulin depletion after the clinical onset of acute-onset type 1 diabetes in Japanese patients: the TIDE-J study.","authors":"Tomoko Ebisuno, Megumi Tachibana, Akihisa Imagawa, Norio Kanatsuna, Jungo Terasaki, Norio Abiru, Takuya Awata, Hiroshi Ikegami, Yoichi Oikawa, Haruhiko Osawa, Takeshi Katsuki, Eiji Kawasaki, Junji Kozawa, Tetsuro Kobayashi, Akira Shimada, Kazuma Takahashi, Daisuke Chujo, Kyoichiro Tsuchiya, Kan Nagasawa, Tomoyasu Fukui, Kazuki Yasuda, Hisafumi Yasuda, Hiroshi Kajio, Toshiaki Hanafusa","doi":"10.1007/s13340-024-00764-z","DOIUrl":"10.1007/s13340-024-00764-z","url":null,"abstract":"<p><strong>Introduction: </strong>Type 1 diabetes is often accompanied by autoimmune thyroid disease. We aimed to investigate the clinical characteristics of Japanese patients with acute-onset type 1 diabetes and thyroid autoantibodies, focusing on decreased endogenous insulin secretion.</p><p><strong>Materials and methods: </strong>We examined 80 patients with acute-onset type 1 diabetes, classifying them into two groups with and without thyroid autoantibodies and compared the clinical characteristics of the two groups. A fasting serum C-peptide immunoreactivity (CPR) of less than 0.1 ng/mL was defined as insulin depletion.</p><p><strong>Results: </strong>In patients with thyroid autoantibodies, the median fasting serum CPR levels at the fourth year after the onset of type 1 diabetes were significantly lower than in those without thyroid autoantibodies (<i>p </i>= 0.02). The cumulative incidence of insulin depletion at 5 years of duration after diagnosis of type 1 diabetes was significantly higher in thyroid autoantibody-positive group than in thyroid autoantibody-negative group (<i>p</i> = 0.01). In the Cox proportional models adjusted for selected baseline factors (age, sex, and BMI), the presence of thyroid autoantibodies did not increase the risk of insulin depletion within 5 years after the onset. However, in bivariate Cox proportional hazards models that investigated the association between thyroid autoantibodies and each baseline factor, the presence of thyroid autoantibodies significantly increased the risk of insulin depletion.</p><p><strong>Conclusions: </strong>Our study showed that Japanese patients with acute-onset type 1 diabetes and positive for thyroid autoantibodies had a higher risk of insulin deficiency within 5 years after the onset than those without thyroid autoantibodies.</p>","PeriodicalId":11340,"journal":{"name":"Diabetology International","volume":"16 1","pages":"39-49"},"PeriodicalIF":1.2,"publicationDate":"2024-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11769878/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143058394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"General aspects of genetic studies on diabetes mellitus.","authors":"Shiro Maeda","doi":"10.1007/s13340-024-00763-0","DOIUrl":"10.1007/s13340-024-00763-0","url":null,"abstract":"","PeriodicalId":11340,"journal":{"name":"Diabetology International","volume":"15 4","pages":"677-678"},"PeriodicalIF":1.2,"publicationDate":"2024-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11513063/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142521274","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Causes of death in Japanese patients with diabetes based on the results of survey of 68,555 cases during 2011-2020: committee report on causes of death in diabetes mellitus, Japan Diabetes Society (English version).","authors":"Jiro Nakamura, Narihito Yoshioka, Hideki Katagiri, Kohjiro Ueki, Toshimasa Yamauchi, Nobuya Inagaki, Yukio Tanizawa, Eiichi Araki, Takeo Nakayama, Hideki Kamiya","doi":"10.1007/s13340-024-00736-3","DOIUrl":"10.1007/s13340-024-00736-3","url":null,"abstract":"&lt;p&gt;&lt;p&gt;The principal causes of death among 68,555 patients with diabetes and 164,621 patients without diabetes who died in 208 hospitals throughout Japan between 2011 and 2020 were determined based on a survey of hospital records. 1. The most frequent cause of death in patients with diabetes was malignant neoplasms (38.9%) (lung 7.8%, pancreas 6.5%, liver 4.1%), followed, in order of descending frequency, by infectious diseases (17.0%) and then vascular diseases (10.9%) (cerebrovascular diseases 5.2%, ischemic heart diseases 3.5%, renal failure 2.3%). The proportion of deaths from malignant neoplasms and vascular diseases has trended upward and downward, respectively. Almost all deaths from ischemic heart diseases were due to myocardial infarction, and the proportion of deaths from heart diseases other than ischemic heart diseases was relatively high (9.0%), with most cases due to heart failure. Diabetic coma associated with hyperglycemia accounted for only 0.3% of deaths. 2. The proportion of deaths from malignant neoplasms, infectious diseases, renal failure, ischemic heart diseases, and heart failure was significantly higher in patients with diabetes than in those without diabetes, and the proportion of deaths from cerebrovascular diseases was significantly lower in patients with diabetes. 3. In regard to the relationship between the age and cause of death in patients with diabetes, malignant neoplasms were the most frequent cause of death in all age groups, and the incidence was around 50% for those in their 50s and 60s. The incidence of death due to infectious diseases was highest in patients older than their 70s. The incidence of death due to vascular diseases for patients in their 40s and 50s was higher than that due to infectious diseases. The highest incidence of death due to ischemic heart diseases was observed for patients in their 40s, and that due to renal failure and heart failure in patients older than their 70s. 4. Compared to patients without diabetes, patients with diabetes demonstrated a higher incidence of death due to pancreas cancer, infectious diseases, renal failure, ischemic heart diseases and heart failure and lower incidence of death due to cerebrovascular diseases in all age groups. 5. The average age at death of patients with diabetes was 74.4 years old in men and 77.4 years old in women, which were lower than the average lifespan of the Japanese general population in 2020 by 7.2 and 10.3 years, respectively. However, these differences were smaller than in previous surveys. 6. The average age at death due to all causes, especially due to ischemic heart diseases, cerebrovascular diseases, heart failure, infectious diseases, and diabetic coma, was lower in patients with \"poorer\" glycemic control than in those with \"better\" glycemic control. 7. In the total survey population, the average age at death of patients with diabetes was significantly higher than that of patients without diabetes. The average age at death due to ","PeriodicalId":11340,"journal":{"name":"Diabetology International","volume":"15 4","pages":"641-665"},"PeriodicalIF":1.2,"publicationDate":"2024-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11512948/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142521267","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Validity of the international physical activity questionnaire short form for assessing physical activity in Japanese adults with type 1 diabetes.","authors":"Hiroto Honda, Naoko Hashimoto, Masako Zenibayashi, Akihiko Takeda, Takehito Takeuchi, Akane Yamamoto, Yushi Hirota","doi":"10.1007/s13340-024-00759-w","DOIUrl":"10.1007/s13340-024-00759-w","url":null,"abstract":"<p><strong>Objective: </strong>To examine the validity of the International Physical Activity Questionnaire short form (IPAQ-SF) against an objective method for assessing physical activity (PA) in Japanese adults with type 1 diabetes (T1D).</p><p><strong>Methods: </strong>This cross-sectional study included 126 adults with T1D (aged 20-74 years). The participants wore a triaxial accelerometer for 7 consecutive days and completed the IPAQ-SF (a recall survey for the last 7 days) on the day following the 7-day accelerometer period. This ensured alignment between the periods assessed by both the methods.</p><p><strong>Results: </strong>A total of 112 participants were analyzed. The IPAQ-SF group had lower daily time in sedentary behavior (SB), total moderate-intensity PA (MPA) (including walking), vigorous-intensity PA (VPA), total PA (including walking), and daily metabolic equivalent (MET)-min in total PA than those in the accelerometer group. Significant correlations were observed between the methods for all variables: daily time in SB, total MPA, VPA, total PA, and daily MET-min in total PA (<i>ρ</i> = 0.203-0.527). In addition, walking time reported in the IPAQ-SF correlated with the step counts recorded by the accelerometer (<i>ρ</i> = 0.444). However, among these parameters, only daily time in VPA was able to provide acceptable levels of validity (≥ 0.50) and predict values recorded by the accelerometer.</p><p><strong>Conclusion: </strong>These results indicate that the IPAQ-SF scores have a weak correlation with each type of accelerometer-measured PA, while the IPAQ-SF may underestimate each type of PA compared to an accelerometer in Japanese adults with T1D.</p><p><strong>Supplementary information: </strong>The online version contains supplementary material available at 10.1007/s13340-024-00759-w.</p>","PeriodicalId":11340,"journal":{"name":"Diabetology International","volume":"16 1","pages":"30-38"},"PeriodicalIF":1.2,"publicationDate":"2024-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11769920/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143058104","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}